过去一年中添加的文章,按日期排序

Genetic Reduction of IRF5 Expression after Disease Initiation Reduces Disease in a Mouse Lupus Model by Impacting Systemic and End-Organ Pathogenic Pathways

A Pellerin, Y Tan, S Lu, RG Bonegio… - The Journal of …, 2023 - journals.aai.org
279 天前 - … and an impaired ability of myeloid cells in the kidney to produce inflammatory
cytokines. Overall, our findings support consideration of IRF5 as a therapeutic target in SLE. …

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T

V Chasov, E Zmievskaya, I Ganeeva, E Gilyazova… - 2023 - preprints.org
279 天前 - … The elevated levels of these cytokines in serum of SLE patients were found to
correlate … Targeting of cytokines is one more approach in addition to above-mentioned of SLE

The Emerging Role of Chimeric Antigen Receptor Therapies in the Treatment of Autoimmune Disorders

S Bloodworth - jmsgr.tamhsc.edu
280 天前 - … identifiable off-target toxicity or related cytokine storm. Lee, … systemic lupus
erythematosus achieved complete remission after receiving the currently approved CART19 therapy

Autoimmune responses and therapeutic interventions for systemic lupus erythematosus: a comprehensive review

SP Pandey, R Bhaskar, SS Han… - … -Drug Targets  …, 2024 - ingentaconnect.com
282 天前 - … hormones trigger the onset of SLE pathogenesis in genetically susceptible individuals
cytokines, macrophages, T cells, and B cells. Diagnosis and clinical investigations of SLE

Immune podocytes in the immune microenvironment of lupus nephritis

R Liu, X Wen, X Peng, M Zhao… - Molecular Medicine …, 2023 - spandidos-publications.com
283 天前 - … evaluates podocytes as a potential therapeutic target for LN. … Systemic lupus
erythematosus (SLE) is a chronic … anti-nucleosome antibodies) and cytokines they produce. T cells …

[HTML][HTML] Gene signature from cutaneous autoimmune diseases provides potential immunotherapy-relevant biomarkers in melanoma

KH Chun, YC Park, N Hwang, BK Yoon, J Kim… - Scientific Reports, 2023 - nature.com
285 天前 - … of skin immune cells in systemic lupus erythematosus (SLE), atopic dermatitis (AD),
and … SLE, AD, and PS, confirming that dendritic cells produce pro-inflammatory cytokines to …

[HTML][HTML] HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases

W Ren, L Zhao, Y Sun, X Wang, X Shi - Molecular Medicine, 2023 - Springer
292 天前 - cytokines and eliciting inflammatory responses. The potential of HMGB1 and TLRs
as therapeutic targetsSystemic lupus erythematosus (SLE), an autoimmune disease closely …

Molecular consideration relevant to the mechanism of the comorbidity between psoriasis and systemic lupus erythematosus

Y Qu, D Li, W Liu, D Shi - … and Therapeutic Medicine, 2023 - spandidos-publications.com
299 天前 - cytokines with effector Th17 cells, T regulatory cells, as well as B cells. In addition,
the therapeutic … , and has also become evident in SLE. However, the mechanisms have not …

31 Other targets: expectations from research on pathogenic mechanisms

T Dörner - 2023 - lupus.bmj.com
300 天前 - … as other proinflammatory cytokines and … in SLE may be identified as targets for
treatment, use of bispecific antibodies12 may hold promise to improve selective immune therapy

MiR-21 Regulation of Systemic Autoimmunity and Immunity

K Bricker - 2023 - etda.libraries.psu.edu
302 天前 - … Abstract: Systemic lupus erythematosus (SLE) is a … its potential as a therapeutic
target. Principle investigations of … cells produced less inflammatory cytokines and had reduced …